

Earlier Cancer Detection for Better Outcomes


78% Cancer Deaths
Not Covered By **Recommended Screening**¹

4Times
Higher Survival **With Early Diagnosis**²

Introducing Lucence**INSIGHT™**

LucenceINSIGHT™ is based on a proprietary amplicon-based technology to screen for the risks of 10 cancers with a sensitivity of 73% and specificity of 98.5%³.

Prospective data in 10,006 individuals supports the safety of amplicon-based testing as an initial cancer screen⁴.



CANCER TYPES
10

SPECIFICITY
98.5%

The test detects cancer-associated alterations circulating in blood. Advanced sequence analysis predicts the site of origin. The report will present your result as Areas of Concern, with an accuracy of 90%³.

Tumor Origin Prediction
90%

Turnaround Time
12-18Days

Available in the following panels:

	LUCENCE INSIGHT™ PLUS	LUCENCE INSIGHT™
LUNG	✓	✓
BREAST	✓	✓
COLORECTAL	✓	✓
PROSTATE	✓	✓
LIVER	✓	✓
NOSE	✓	✓
BILE DUCT	✓	✓
PANCREAS	✓	✓
ACUTE MYELOID LEUKEMIA	✓	
CHRONIC MYELOID LEUKEMIA	✓	

Lucence**INSIGHT™ PLUS** also covers the following:

CHIP* ✓

* Clonal hematopoiesis of indeterminate potential (CHIP) is a common age-related bone marrow phenomenon associated with both an increased risk of developing cardiovascular disease and hematologic cancers.



LucenceINSIGHT™ is a screening test to evaluate cancer risk. This test is not intended for use as a diagnostic tool and should not replace the standard of care screening routine or the care of a healthcare provider. Intended for access and use by Singapore physicians only. Visit Lucence.com to find out more.

This pamphlet is not intended for the purpose of providing medical advice. All information, content, and material of this pamphlet are for informational purposes only and are not intended to serve as a substitute for the consultation, diagnosis, and/or medical treatment of a qualified physician or healthcare provider. Always seek the advice of your physician or other qualified healthcare provider for information you may need regarding a medical condition.

REFERENCES 1. GLOBOCAN 2020. 2. American Cancer Society. <https://www.cancer.org/cancer.html> 3. Data on file. 4. Lennon, A.M. et. al. (2020). Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science. doi: 10.1126/science.abb9601